Page 70 - பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் Today - Breaking & Trending Today

Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis

Date Time
Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact through the CREB1 protein to promote metastasis and tumor growth. Blocking CREB1 in preclinical models reversed these effects and reduced metastases, suggesting an important new therapeutic target for the deadly cancer.
“To our knowledge, this is the first study to show how these two major genetic drivers work together to promote tumor growth and metastasis,” Kim said. “We learned that signaling downstream of mutant KRAS directly promotes mutant p53 activity. This discovery provides not only a new therapeutic target but unveils a vast transcriptional network that is activated downstream of these mutant proteins.” ....

United States , Bingbing Dai , Gigi Lozano , Amandar Wasylishen , Jithesh Augustine , Jasonb Fleming , Yaan Kang , Timothyp Heffernan , Florencia Mcallister , Michael Kim , Christopher Bristow , Kendra Allton , Shunbin Xiong , Jenying Deng , Eugene Koay , Yun Zhang , Tarag Hughes , Michellec Barton , Guillermina Lozano , Christian Siangco , Xinqun Li , Anirban Maitra , Sheikh Ahmed Bin Zayed Al Nahyan Center , University Of Texas Md Anderson Cancer Center , National Institutes Of Health , Rose Cole Charitable Pria Foundation ,

Synlogic Presents Data from SYNB1891 Phase 1 Trial at American Association for Cancer Research (AACR) Annual Meeting

Synlogic Presents Data from SYNB1891 Phase 1 Trial at American Association for Cancer Research (AACR) Annual Meeting
- Data demonstrates activation of STING pathway in patients -
- Combination arm of Phase 1 study of SYNB1891 ongoing -
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on SYNB1891 for the treatment of solid tumors and lymphoma during the American Association for Cancer Research (AACR) annual meeting, April 10-15, 2021.
SYNB1891 is an investigational drug being evaluated in an ongoing Phase 1 clinical trial for the treatment of solid tumors and lymphoma. SYNB1891 is composed of an engineered Synthetic Biotic strain of E. coli Nissle that produces cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. Th ....

United Kingdom , United States , Filip Janku , Division Of Cancer Medicine , American Association For Cancer Research , University Of Texas Md Anderson Cancer Center , Synlogic Inc , Department Of Investigational Cancer Therapeutics , American Association , Cancer Research , Synthetic Biotic , Associate Professor , Investigational Cancer Therapeutics , Cancer Medicine , Synthetic Biotics , Private Securities Litigation Reform Act , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , பிரிவு ஆஃப் புற்றுநோய் மருந்து , அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , அமெரிக்கன் சங்கம் , புற்றுநோய் ஆராய்ச்சி , செயற்கை உயிரியல் , இணை ப்ரொஃபெஸர் , புற்றுநோய் மருந்து ,

Resistance to Immunotherapy in Patients with Urothelial Bladder Cancer Is Traced to Specific Sets of Immune Cells

Resistance to Immunotherapy in Patients with Urothelial Bladder Cancer Is Traced to Specific Sets of Immune Cells
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United States , Matthew Galsky , Bristol Myers Squibb , Icahn School Of Medicine At Mount Sinai , University Of Texas Md Anderson Cancer Center , Tisch Cancer Institute , Translational Research , Bladder Cancer Center , Clinical Cancer Research , Medical Oncology , Icahn School , Associate Director , Tisch Cancer , Mount Sinai Led , National Cancer Institute , National Institutes , ஒன்றுபட்டது மாநிலங்களில் , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , இக்ஹ்ன் பள்ளி ஆஃப் மருந்து இல் ஏற்ற சினை , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , டிஷ் புற்றுநோய் நிறுவனம் , மொழிபெயர்ப்பு ஆராய்ச்சி , சிறுநீர்ப்பை புற்றுநோய் மையம் , மருத்துவ புற்றுநோய் ஆராய்ச்சி , மருத்துவ புற்றுநோயியல் , இக்ஹ்ன் பள்ளி ,

Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis

Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.

United States , Bingbing Dai , Gigi Lozano , Amandar Wasylishen , Jithesh Augustine , Jasonb Fleming , Yaan Kang , Timothyp Heffernan , Florencia Mcallister , Michael Kim , Christopher Bristow , Kendra Allton , Shunbin Xiong , Jenying Deng , Eugene Koay , Yun Zhang , Tarag Hughes , Michellec Barton , Guillermina Lozano , Christian Siangco , Xinqun Li , Anirban Maitra , Sheikh Ahmed Bin Zayed Al Nahyan Center , University Of Texas Md Anderson Cancer Center , National Institutes Of Health , Rose Cole Charitable Pria Foundation ,

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi's novel investigational IL-2

Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi s novel investigational IL-2
Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi s novel investigational IL-2
Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1
THOR-707, a precisely PEGylated, engineered version of IL-2 built on Sanofi s Synthorin technology platform, is being studied in a trial of adults with advanced or metastatic solid tumors
PARIS - April 9, 2021 - Interim data from a first-in-human trial evaluating the safety, therapeutic activity and maximum tolerable dose of THOR-707 (SAR444245), a highly differentiated not-alpha interleukin-2 (IL-2) candidate, as a monotherapy and in combination with anti-PD-1, will be presented Saturday, April 10 as a l ....

United States , France General , Eva Schaefer Jansen , Arnaud Delepine , Suzanne Greco , Felix Lauscher , Sanofi Synthorin , John Reed , Filip Janku , Fara Berkowitz , Sally Bain , Division Of Cancer Medicine , Global Head Of Research Development , American Association For Cancer Research , University Of Texas Md Anderson Cancer Center , Merck Co , Department Of Investigational Cancer Therapeutics , American Association , Cancer Research , Global Head , Natural Killer , Associate Professor , Investigational Cancer Therapeutics , Cancer Medicine , Cancer Center , Expanded Genetic Alphabet ,